scholarly journals Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Weijian Ke ◽  
Liehua Liu ◽  
Juan Liu ◽  
Ailing Chen ◽  
Wanping Deng ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Cell Function ◽  
Subcutaneous Insulin ◽  
Newly Diagnosed ◽  
Short Term

The objective of this paper is to investigate the effects of liraglutide in combination with short-term continuous subcutaneous insulin infusion (CSII) therapy on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus (T2DM). Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks. Blood glucose control, homeostasis model assessment (HOMA) indices, and acute insulin response (AIR) were compared between the two groups. The patients in CSII + Lira group achieved euglycemia with equivalent insulin dosage in shorter time (1 (0) versus 2 (3) days,P=0.039). HbA1c at the end of study was comparable between two groups (6.3±0.7% versus6.0±0.5%, for CSII alone group and CSII + Lira group, resp.,P=0.325). The increment of AIR was higher in CSII + Lira group (177.58 (351.57) μU·min/mL versus 58.15 (51.30) μU·min/mL,P<0.001). However, after stopping liraglutide, its effect on beta cell function disappeared completely. Liraglutide combined with short-term CSII was effective in further improving beta cell function, but the beneficial effects did not sustain after suspension of the therapy.

scholarly journals Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity

2011 ◽  
Vol 164 (6) ◽  
pp. 905-910 ◽  
Author(s):  
Ke Li ◽  
Ling Li ◽  
Mengliu Yang ◽  
Hua Liu ◽  
Dongfang Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Sensitivity ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Subcutaneous Insulin ◽  
Newly Diagnosed ◽  
Short Term

ObjectiveTo investigate the effects of short-term continuous subcutaneous insulin infusion (CSII) on plasma vaspin levels in patients with newly diagnosed type 2 diabetes mellitus (T2DM).MethodThirty patients with severe newly diagnosed T2DM, 37 subjects with impaired glucose tolerance (IGT) and 38 gender-, age- and body mass index (BMI)-matched normal GT (NGT) controls participated in the study. The T2DM group was treated with CSII for 2 weeks. Euglycemic–hyperinsulinemic clamps were performed in 16 subjects of the T2DM group. Plasma vaspin concentrations were measured with a commercial ELISA kit. The relationship between plasma vaspin levels and metabolic parameters was also analyzed.ResultsFasting plasma vaspin levels were higher in the T2DM group than in IGT and NGT groups (1.83±0.55 vs 0.51±0.21 vs 0.53±0.24 μg/l, P<0.05), but there was no difference between IGT and NGT groups. In T2DM patients, fasting plasma vaspin concentrations were significantly decreased after CSII treatment for 2 weeks (1.83±0.55 vs 1.19±0.57 μg/l, P<0.05), accompanied by significant amelioration of insulin sensitivity and glucose control. The changes in plasma vaspin levels were positively associated with the amelioration of insulin resistance (IR) shown by the changes in homeostasis model assessment of IR.ConclusionPlasma vaspin level is associated with IR and is significantly reduced following short-term CSII treatment.

Decline in Beta-Cell Function among Adolescents with Type 2 Diabetes Mellitus

JMS SKIMS ◽  
2017 ◽  
Vol 20 (2) ◽  
pp. 115-116
Author(s):  
Shariq Rashid Masoodi
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Secretion ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Fasting Glucose ◽  
Newly Diagnosed ◽  
Annual Decline ◽  
Over Time

It is well known that beta-cell function declines over time in adults with type 2 diabetes mellitus (T2DM). The beta-cell dysfunction, initially characterized by impairment in the first phase of insulin secretion following glucose stimulation, advances to a decline in second phase insulin secretion as the disease progresses. But whether this decline in beta-cell function occurs in adolescents with T2DM is uncertain. Investigators prospectively compared beta-cell functioning over time between 39 adolescents with newly diagnosed T2DM (mean age, 15 years; body-mass index z-score, 2.4) and 32 obese adolescents without T2DM of comparable body-mass index, gender, and race (mean age, 14) during a 2-year period. Recently, researchers from Duke University School of Medicine, Durham North Carolina reported that adolescents with newly diagnosed T2DM had a 25% annual decline in beta-cell function despite receiving treatment. In this study, the results of which were first presented at the American Diabetes Association (ADA), the participants were adolescents with T2DM, more than half of whom were being treated with insulin whereas 80% were taking oral anti-diabetes medications. Beta-cell function in this study, assessed at baseline and 6, 12, and 24 months was measured by insulin secretion in response to an intravenous glucose load adjusted for insulin sensitivity (disposition index). The authors observed that adolescents with T2DM had significantly higher levels of both insulin resistance and fasting glucose at baseline compared with controls. But during the two-year study, the study subjects experienced a significant increase in fasting glucose and a 25 percent annual decline in disposition index. Understandably, both these indicators remained unchanged among the controls. JMS 2017;20(2):116

scholarly journals Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects

PLoS ONE ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. e0231190
Author(s):  
Monica Shah ◽  
May M. Adel ◽  
Bettina Tahsin ◽  
Yannis Guerra ◽  
Leon Fogelfeld
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Healthy Subjects ◽  
Cell Function ◽  
Short Term
Sign in / Sign up

Export Citation Format

Share Document